Business Wire

CA-DIALPAD

16.12.2021 15:02:04 CET | Business Wire | Press release

Share
Dialpad Raises $170 Million and Increases Valuation to $2.2 Billion as it Leads New Era of AI-Powered Communications

Dialpad Inc. , the industry leader in AI-powered cloud communications and collaboration, today announced $170 million in funding. The amount raised and valuation of $2.2 billion reflects the increasing importance of a truly unified approach to business communications. To date, Dialpad has raised $418 million in capital.

ICONIQ Capital leads the funding round which includes participation from Amasia, GV, OMERS Growth Equity, Work-Bench, Section 32, and T-Mobile Ventures. Dialpad will use this funding to invest in the further development and application of native artificial intelligence (AI) throughout its unified platform; hiring top talent across data engineering, natural language processing, machine learning and customer-facing roles to support its rapid global growth.

“Dialpad is the world’s most advanced AI-powered communications, collaboration, and contact center platform, providing a customer- and cloud-first solution that enables more efficient and effective conversations,” said Craig Walker, founder and CEO, Dialpad. “This latest round of funding, and increased valuation, showcases Dialpad’s continued momentum and strengthens our dedication to helping companies scale and enterprises thrive in today’s hybrid, work-from-anywhere world.”

“Dialpad is at the forefront of cloud-based, native AI communications, collaboration, and contact center solutions. ICONIQ Capital is proud to again invest in Dialpad’s vision to deliver streamlined communications combined with crucial data-driven insights all through one application,” said Will Griffith, Founding Partner, ICONIQ Capital. “As the creator of Google Voice, Craig Walker knows what it means to disrupt an entire category. Walker recognized the pain points consumers had communicating at scale in the cloud. Now, he is applying that same philosophy with Dialpad, extending it to the enterprise and is once again disrupting the status quo.”

Dialpad is the one place for truly unified Communications as a Service (TrueCaaS™), offering companies and employees the ability to work smarter — not harder — from anywhere on any device. In today’s distributed world, teams need one seamless solution for productive collaboration that also avoids the growing phenomenon of “app overload”. Simple to deploy and backed up with Voice Intelligence (Vi™) to create a searchable archive of every call, Dialpad delivers all modes of business communications through a single pane of glass.

“Customer adoption of Dialpad’s AI-powered TrueCaaS platform is at an all time high and is accelerating,” said Mike Kourey, Chief Financial Officer, Dialpad. “This $170 million financing round further fuels our unparalleled innovation engine and global expansion, advancing Dialpad’s comprehensive vision for the future of work, business communications and collaboration, and customer experience.”

The funding round is the latest development in a year of significant milestones for Dialpad including growth, global expansion, partnerships and acquisitions.

Additional Resources

Social Networks:

About Dialpad

Dialpad is the global leader in AI communications for business, transforming how the world works together. Dialpad customers benefit from truly unified business and customer communications, including a cloud business phone system, text and team messaging, video meetings, and the world’s most advanced AI-powered contact center — all in one beautiful app. More than 7,000 innovative brands and millions of people use Dialpad to connect their teams from anywhere including Motorola Solutions, Netflix, T-Mobile, Uber and WeWork. Visit www.dialpad.com for more information and to request a demo.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release

Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye